Merck-backed lab Hilleman scouts for rotavirus vaccine partners in India

If Hilleman Labs is successful in scouting for a rotavirus vaccine partnership, India might see a new force added to its efforts to fight child and infant mortality caused by the deadly virus.

Hilleman, a Delhi-based vaccine research organization co-owned by U.S. drug maker Merck & Co. and British charitable foundation Wellcome Trust, is in search for pharma partners to manufacture and market a candidate vaccine to fight the life-threatening virus.

Perhaps the most essential feature of Hilleman's oral vaccine--currently in the Phase I/II clinical trial stage--is that it’s heat-stable. If it reaches the market, such an improvement would eliminate the stringent cold-chain storage and transportation conditions usually required of vaccines, thus lowering the cost.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The not-for-profit JV, which focuses on researching low-cost vaccines to be distributed in developing countries, does not have a manufacturing unit of its own, CEO Davinder Gill told India's Livemint, and it doesn’t intend to build one in the immediate future. It's counting on milestone royalties based on research for revenues to continue its work.

Gill said the lab is looking for “affordable and safe” partnerships for manufacturing its vaccines. Besides the rotavirus vaccine, the organization is also working on vaccines against cholera and meningitis.

Rotavirus infections are the leading cause of severe diarrhea among children 5 years old and younger. About 334,000 annual deaths among children in India are attributable to diarrheal diseases. Of those, about a third is estimated to be caused by rotavirus, according to a study posted by the World Health Organization in 2012.

Under the current Modi administration, India has been stepping up its efforts to increase vaccine delivery through its Universal Immunization Programme in an attempt to reduce child mortality dramatically. The country’s Health Ministry in March launched its first, indigenous rotavirus vaccine, Rotavac, manufactured by Bharat Biotech. That vaccine, though a cheap one--about $3 per child compared with around $45 for vaccines from international pharmaceutical companies--has to be stored at -20°C (-4 °F) till the expiry date.

Besides Bharat, other vaccine manufacturing companies in India include Sanofi-owned Shantha, GlaxoSmithKline, among others.

Related Articles:
India's local rotavirus vaccine launched to combat death linked to diarrhea
Takeda, Hilleman eye low-cost vaccine space
Bharat's $1 rotavirus vaccine rolls out in India to challenge GSK, Merck
GSK's rotavirus vaccine as effective as Merck shot

 

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.